|
Session 27-Oral Abstracts
TB Prevention and Treatment and Complications of HIV and ART
Thursday, 9:30-11:00 am; Room 3022 |
| 9:30 am 102 |
Effectiveness of Isoniazid Preventive Therapy in Reducing Mortality in Patients on ART
Craig Innes*1, S Charalambous1, M Felix1, K Fielding2, A Grant2, and G Churchyard1,2
1Aurum Inst, South Africa and 2London Sch of Hygiene and Tropical Med, UK |
| 9:45 am 103 |
Efficacy of a 6-month vs a 36-month Regimen for Prevention of TB in HIV-infected Persons in India: A Randomized Clinical Trial
Soumya Swaminathan*, P Menon, V Perumal, R K Santhanakrishnan, R Ramachandran, P Chinnaiah, S Iliayas, N Gopalan, P Chandrasekaran, and P Narayanan
Tuberculosis Res Ctr, Chennai, India |
| 10:00 am 104LB |
Randomized, Placebo-controlled Trial of 6 vs 36 Months Isoniazid TB Preventive Therapy for HIV-infected Adults in Botswana
Taraz Samandari*1,2, B Mosimaneotsile1, T Agizew1, S Nyirenda3, Z Tedla1, T Sibanda1, O Motsamai4, N Shang2, P Kilmarx2, C Wells2, and IPT Trial Study Group
1BOTUSA, Gaborone, Botswana; 2CDC, Atlanta, GA, US; 3BOTUSA, Francistown, Botswana; and 4Botswana Ministry of Hlth, Gaborone |
| 10:15 am 105 |
Randomized Trial of a 6-month Punctuated Course of ART in Ugandan HIV+ Adults with Pulmonary TB and CD4 >350
M Walusimbi1, E Charlebois2, R Lin2, P Srikantiah2, D Dobbs1, Harriet Mayanja-Kizza*1,3, H Boom1,4, R Mugerwa1,3, D Havlir2, C Whalen4, and PART Study
1Uganda-Case Western Reserve Univ Res Collaboration, Kampala; 2Univ of California, San Francisco, US; 3Makerere Univ, Kampala, Uganda; and 4Case Western Reserve Univ, Cleveland, OH, US |
| 10:30 am 106LB |
Bone and Limb Fat Outcomes of ACTG A5224s, a Substudy of ACTG A5202: A Prospective, Randomized, Partially Blinded Phase III Trial of ABC/3TC or TDF/FTC with EFV or ATV/r for Initial Treatment of HIV-1 Infection
Grace McComsey*1, D Kitch2, E Daar3, C Tierney2, N Jahed4, P Tebas5, L Myers6, P Sax7, and AACTG Study A5224
1Case Western Reserve Univ, Cleveland, OH, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Los Angeles Biomed Res Inst at Harbor-UCLA, Torrance, US; 4Social & Sci Systems, Inc, Silver Spring, MD, US; 5Univ of Pennsylvania, Philadelphia, US; 6Frontier Sci and Tech Res Fndn, Amherst, NY, US; and 7Brigham and Women`s Hosp, Harvard Med Sch, Boston, MA, US |
| 10:45 am 107LB |
Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: The EuroSIDA Study
Ole Kirk*1, A Mocroft2, P Reiss3, S De Wit4, D Sedlacek5, M Beniowski6, J Gatell7, A Phillips2, B Ledergerber8, J Lundgren1,9, and for the EuroSIDA Study Group
1Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; 2Royal Free and Univ Coll London Med Sch, UK; 3Academic Med Ctr, Univ of Amsterdam, The Netherlands; 4Ctr Hosp Univ Saint-Pierre, Brussels, Belgium; 5Charles Univ Hosp, Plzen, Czech Republic; 6Specialistic Hosp, Chorzow, Poland; 7Hosp Clin, Barcelona, Spain; 8Univ Hosp Zurich, Switzerland; and 9Rigshospitalet, Copenhagen, Denmark |
|
